Most Popular Articles : HemaSphere

Journal Logo

Most Popular Articles

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

Dimopoulos, Meletios A.; Moreau, Philippe; Terpos, Evangelos; More

HemaSphere. 5(2):e528, February 2021.

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Ghia, Paolo; Pluta, Andrzej; Wach, Małgorzata; More

HemaSphere. 6(12):e801, December 2022.

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Nagler, Arnon; Labopin, Myriam; Swoboda, Ryszard; More

HemaSphere. 6(11):e790, November 2022.

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Sonneveld, Pieter; Zweegman, Sonja; Cavo, Michele; More

HemaSphere. 6(10):e786, October 2022.

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

Valent, Peter; Akin, Cem; Hartmann, Karin; More

HemaSphere. 5(11):e646, November 2021.

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Tettero, Jesse M.; Freeman, Sylvie; Buecklein, Veit; More

HemaSphere. 6(1):e676, January 2022.

P545: CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND TRISOMY 19

Kayser, S.; Martínez-Cuadrón, D.; Rodriguez-Veiga, R.; More

HemaSphere. 6:444-445, June 2022.

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL

Dimopoulos, MA; Oriol, A; Nahi, H; More

HemaSphere. 6:13, April 2022.

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

Baliakas, Panagiotis; Espinet, Blanca; Mellink, Clemens; More

HemaSphere. 6(4):e707, April 2022.

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet

Itzykson, Raphael; Fenaux, Pierre; Bowen, David; More

HemaSphere. 2(6):e150, December 2018.

CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission

Kharfan-Dabaja, Mohamed A.; Labopin, Myriam; Bazarbachi, Ali; More

HemaSphere. 6(11):e788, November 2022.

Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone

Efentakis, Panagiotis; Lamprou, Sofia; Makridakis, Manousos; More

HemaSphere. 6(11):e791, November 2022.

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group

Borchmann, Peter; Moccia, Alden; Greil, Richard; More

HemaSphere. 6:1-2, October 2022.

Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients

Le Pannérer, Marguerite-Marie; Diesch, Jeannine; Casquero, Raquel; More

HemaSphere. 6(11):e792, November 2022.

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy

Argnani, Lisa; Broccoli, Alessandro; Pellegrini, Cinzia; More

HemaSphere. 6(12):e798, December 2022.

Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting

Pandzic, Tatjana; Ladenvall, Claes; Engvall, Marie; More

HemaSphere. 6(8):e761, August 2022.

S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY

Short, N.; Kantarjian, H.; Konopleva, M.; More

HemaSphere. 6:15-16, June 2022.

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies

Kirschner, Martin; Rolles, Benjamin; Crysandt, Martina; More

HemaSphere. 6(11):e787, November 2022.

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment

Mulder, Tom A.; Andersson, Maria L.; Peña-Pérez, Lucía; More

HemaSphere. 6(11):e794, November 2022.

T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial

Diepstra, Arjan; Visser, Lydia; Fortpied, Catherine; More

HemaSphere. 6:1, October 2022.

Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing

Meyers, Sarah; Alberti-Servera, Llucia; Gielen, Olga; More

HemaSphere. 6(4):e700, April 2022.

Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases

Galusic, Davor; Basic-Kinda, Sandra; Pijuk, Andela; More

HemaSphere. 6(12):e807, December 2022.

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

Moskowitz, Alison J.; Shah, Gunjan; Schöder, Heiko; More

HemaSphere. 6:45-46, October 2022.

P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL

Sonneveld, P; Chanan-Khan, A; Weisel, K; More

HemaSphere. 6:12, April 2022.

Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

Herold, Michael; Hoster, Eva; Janssens, Ann; More

HemaSphere. 6(3):e699, March 2022.

Recommendations for Pregnancy in Rare Inherited Anemias

Taher, Ali T.; Iolascon, Achille; Matar, Charbel F.; More

HemaSphere. 4(4):e446, August 2020.

S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY

Rives, S.; Maude, S. L.; Hiramatsu, H.; More

HemaSphere. 6:13-14, June 2022.

Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

Salmanton-García, Jon; Marchesi, Francesco; Glenthøj, Andreas; More

HemaSphere. 6(11):e789, November 2022.

S196: ROPEGINTERFERON ALFA-2B ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES

Gisslinger, H.; Klade, C.; Georgiev, P.; More

HemaSphere. 6:97-98, June 2022.

S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Dickinson, M.; Kwon, M.; Briones, J.; More

HemaSphere. 6:113-114, June 2022.

A Novel t(5;7)(q31;q21)/CDK6::IL3 in Immature T-cell Acute Lymphoblastic Leukemia With IL3 Expression and Eosinophilia

Pierini, Valentina; Bardelli, Valentina; Giglio, Fabio; More

HemaSphere. 6(11):e795, November 2022.

Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions

Valent, Peter; Orfao, Alberto; Kubicek, Stefan; More

HemaSphere. 5(3):e536, March 2021.

The EHA Research Roadmap: Transfusion Medicine

Stanworth, Simon J.; Brand, Anneke; Kaveri, Srini V.; More

HemaSphere. 6(2):e670, February 2022.

Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood KMT2A-rearranged Acute Leukemia

Pilheden, Mattias; Ahlgren, Louise; Hyrenius-Wittsten, Axel; More

HemaSphere. 6(10):e785, October 2022.

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report

Rodeghiero, Francesco; Pabinger, Ingrid; Ragni, Margaret; More

HemaSphere. 3(5):e286, October 2019.

S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL

Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; More

HemaSphere. 6:81-82, June 2022.

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study

Herfarth, Klaus; Borchmann, Peter; Schnaidt, Sven; More

HemaSphere. 2(6):e160, December 2018.

Show: